The ERK2 Mitogen-Activated Protein Kinase Regulates the Timing of Oligodendrocyte Differentiation
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Oligodendrocyte development is tightly controlled by a variety of extracellular growth and differentiation factors. The mitogen-activated protein kinases (MAPKs), ERK1 and ERK2, are critical intracellular signaling molecules important for transducing these extracellular signals. The extracellular signal-regulated kinases (ERKs) are ubiquitously expressed, coordinately regulated, and highly similar, but Erk2 deletion in mice is embryonic lethal whereas Erk1 deletion is not. Several studies have suggested that MAPK signaling is important for oligodendrocyte differentiation, although specific roles for the two ERK isoforms have not been investigated. In this study, we deleted Erk2 in the developing mouse cortex from GFAP-expressing radial glia that generate neurons and oligodendrocytes.In vitro analysis revealed that loss of ERK2 resulted in fewer galactocerebroside-expressing mature oligodendrocytes in cortical cultures.In vivo, a delay in the expression of the myelin protein MBP was observed in the corpus callosum at postnatal day 10 (P10). In contrast,Erk1 deletion did not affect oligodendrocyte differentiation. By P21, MBP expression was restored to wild-type levels, demonstrating that the loss of ERK2 results in a delay but not a complete arrest in the appearance of differentiated oligodendrocytes in vivo. Importantly, both the proliferation and total number of oligodendrocyte progenitor cells (OPCs) appeared normal in the Erk2 conditional knock-out cortex, demonstrating that ERK2 plays a specific role in the timing of forebrain myelination but is not critical for the proliferation or survival of OPCs. Oligodendrocyte-specific deletion of Erk2 also resulted in decreased levels of MBP, indicating a cell-autonomous effect of ERK2 in the oligodendrocyte lineage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345 · cited 1×
“IGF-I and neurotrophins promote the differentiation and/or survival of OPCs (Mozell and McMorris, 1991; Barres et al., 1992; Kumar et al., 1998; Du et al., 2006).”
BackgroundKessaris, N., Fogarty, M., Iannarelli, P., Grist, M., Wegner, M., & Richardson, W. D. (2006) · Nature Neuroscience · doi:10.1038/nn1620 · Cited by 1,195 · cited 1×
“Cre–LoxP fate mapping has demonstrated that there are three waves of OPC generation in the mouse forebrain (Kessaris et al., 2006).”
BackgroundPremyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 2×
“Latestage OPCs can be found in and around demyelinated lesions in multiple sclerosis patients, suggesting that remyelination by adult OPCs is not inhibited as a result of a lack of mobility or recruitment but rather by an inability of these cells to terminally differentiate (Scolding et al., 1998; Wolswijk, 1998; Chan…”
BackgroundDawson, M. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00210-0 · Cited by 927
Kuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
Noble, M., Murray, K., Stroobant, P., Waterfield, M. D., & Riddle, P. (1988) · Nature · doi:10.1038/333560a0 · Cited by 830 · cited 1×
“Platelet-derived growth factor (PDGF) and fibroblast growth factor-2 (FGF-2) are potently mitogenic to OPCs and play important roles in the timing of oligodendrocyte differentiation (Noble et al., 1988; Raff et al., 1988; McKinnon et al., 1990; Bansal and Pfeiffer, 1994).”
BackgroundWolswijk, G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00601.1998 · Cited by 562
Mazzucchelli, C., Vantaggiato, C., Ciamei, A., Fasano, S., Pakhotin, P., Krezel, W., Welzl, H., Wolfer, D. P., Pagès, G., Valverde, O., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00716-x · Cited by 456 · cited 1×
“Erk1 knock-out (Erk1 / ) mice are viable (Mazzucchelli et al., 2002), whereas Erk2 null mice die during embryogenesis (Hatano et al., 2003; Saba-El-Leil et al., 2003; Yao et al., 2003).”
BackgroundAn essential function of the mitogen‐activated protein kinase Erk2 in mouse trophoblast development
Saba‐El‐Leil, M. K., Vella, F. D. J., Vernay, B., Voisin, L., Chen, L., Labrecque, N., Ang, S., & Meloche, S. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor939 · Cited by 366 · cited 1×
“Erk1 knock-out (Erk1 / ) mice are viable (Mazzucchelli et al., 2002), whereas Erk2 null mice die during embryogenesis (Hatano et al., 2003; Saba-El-Leil et al., 2003; Yao et al., 2003).”
BackgroundAxonal Control of Oligodendrocyte Development
Barres, B. A., & Raff, M. C. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.6.1123 · Cited by 360 · cited 2×
“Because neurons participate in the development of oligodendrocytes by regulating their proliferation, differentiation, and survival (Barres and Raff, 1999), it is possible that aberrant signals from ERK2-deficient neurons could contribute to the defects in oligodendrocyte differentiation observed in this study.”
Background
Cited by
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Molecular Control of Oligodendrocyte Development
Elbaz, B., & Popko, B. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.01.002 · Cited by 293
ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?
Buscà, R., Pouysségur, J., & Lenormand, P. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00053 · Cited by 284
Sun, J., & Nan, G. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2962 · Cited by 242
“…that total ERK1/2 activity controls the proliferation of certain late-born progenitor cells and the differentiation of neurons and glia during fetal brain development and that the two may compensate for each other during this process, at least in part, due to their overlapping functions (37,38).”
Guardiola‐Diaz, H. M., Ishii, A., & Bansal, R. (2012) · Glia · doi:10.1002/glia.22281 · Cited by 171
Figlia, G., Gerber, D., & Suter, U. (2018) · Glia · doi:10.1002/glia.23273 · Cited by 165
Zhu, Q., Zhao, X., Zheng, K., Li, H., Huang, H., Zhang, Z., Mastracci, T., Wegner, M., Chen, Y., Sussel, L., et al. (2014) · Development · doi:10.1242/dev.095323 · Cited by 150
Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
Mathews, E. S., & Appel, B. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0726-16.2016 · Cited by 97
Yuen, T. J., Johnson, K. R., Miron, V. E., Zhao, C., Quandt, J., Harrisingh, M. C., Swire, M., Williams, A., McFarland, H. F., Franklin, R. J. M., et al. (2013) · Brain · doi:10.1093/brain/awt024 · Cited by 80
“, 2009), the significance of which is highlighted by recent work showing that ERK2 is essential for timely myelination (Fyffe-Maricich et al., 2011).”
BackgroundGalectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination
Thomas, L., & Pasquini, L. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00297 · Cited by 76
Activin receptors regulate the oligodendrocyte lineage in health and disease
Dillenburg, A., Ireland, G., Holloway, R. K., Davies, C. L., Evans, F. L., Swire, M., Bechler, M. E., Soong, D., Yuen, T. J., Su, G. H., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1813-3 · Cited by 75
“1 3 the 5 TGFβ signaling pathways induced downstream of activin receptors (Rac1 GTPase, p38 MAPK/JNK, PI3K/ AKT, Smad2/3, ERK1/2,) which are also associated with regulation of oligodendroglial lineage responses and myelination [4, 27, 29, 47, 61].”
BackgroundSyed, Y. A., Baer, A., Hofer, M. P., González, G. A., Rundle, J., Myrta, S., Huang, J. K., Zhao, C., Rossner, M. J., Trotter, M. W. B., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201303123 · Cited by 58
Klocke, C., Allen, J. L., Sobolewski, M., Blum, J. L., Zelikoff, J. T., & Cory-Slechta, D. A. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2017.10.004 · Cited by 56
Safina, D., Schlitt, F., Romeo, R., Pflanzner, T., Pietrzik, C. U., Narayanaswami, V., Edenhofer, F., & Faissner, A. (2016) · Glia · doi:10.1002/glia.23009 · Cited by 54
“ERK2 has been specifically shown to regulate MBP expression and ERK2 deletion resulted in myelination delay (Fyffe-Maricich et al., 2011).”
BackgroundMEK1/2 Inhibition Suppresses Tamoxifen Toxicity on CNS Glial Progenitor Cells
Chen, H.-Y., Yang, Y. M., Han, R., & Noble, M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2729-13.2013 · Cited by 18
“This pathway was also of interest in light of findings that although genetic deficiency of ERK2 delays early stages of differentiation of O-2A/OPCs into oligodendrocytes, it has no apparent negative impacts on progenitor cells (Fyffe-Maricich et al., 2011; Guardiola-Diaz et al., 2012).”
Metadata
- Authors
- Fyffe-Maricich, S. L., Karlo, J. C., Landreth, G. E., & Miller, R. H.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2011-01-19
- Volume
- 31
- Issue
- 3
- Pages
- 843-850
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2064595948
- Cited by
- 157
- References
- 15
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.